12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tesetaxel: Phase II started

Genta began the double-blind, placebo-controlled, international Phase II TESEGAST trial to compare 27 mg/m 2 oral tesetaxel on day 1 of a 21-day cycle in combination with Xeloda capecitabine vs. Xeloda alone...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >